Aims Apart from cardiotoxicity, the chemotherapeutic doxorubicin (DOX) induces vascular
toxicity, represented by arterial stiffness and endothelial dysfunction. Both parameters are of …

Clinical and animal studies have demonstrated that chemotherapeutic doxorubicin (DOX)
increases arterial stiffness, a predictor of cardiovascular risk. Despite consensus about DOX …

The clinical use of doxorubicin in cancer is limited by cardiotoxic effects that can lead to
heart failure. Whereas earlier work focused on the direct impact of doxorubicin on …

Doxorubicin (DOX) is a highly effective chemotherapy agent that often causes cardiotoxicity.
Despite a number of extensive studies, the risk for DOX cardiotoxicity remains unpredictable …

Apart from cardiotoxicity, the chemotherapeutic agent doxorubicin (DOX) provokes acute
and long-term vascular toxicity. Dexrazoxane (DEXRA) is an effective drug for treatment of …

Doxorubicin (DOX) is a topoisomerase II inhibitor used in cancer therapy. Despite its
efficacy, DOX causes serious adverse effects, such as short-and long-term cardiotoxicity …

Cancer remains a major public health problem worldwide and was responsible for 9.6
million deaths in 2018. Oncologic treatments such as doxorubicin (Dox) and trastuzumab …

Background Doxorubicin (DOX)-related cardiotoxicity may expose cancer survivors to
increased risk of cardiovascular morbidity and mortality. Here, we characterized the time …

Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …

Doxorubicin (DOX) has been reported to be a very potent and effective anticancer agent.
However, clinical treatment with DOX has been greatly limited due to its cardiotoxicity …